InnocsAI

InnocsAI is an oncology-focused biotechnology company specializing in next-generation chimeric antigen receptor T-cell (CAR-T) therapies and AI-driven diagnostics. The company's lead therapeutic candidate, IBC101, is a bivalent CAR-T therapy targeting CD19 and CD22, currently undergoing Phase 1/2a clinical evaluation for relapsed or refractory B-cell malignancies. InnocsAI also develops the INNOCS AI platform, which utilizes a proprietary panel of 16 metabolomic biomarkers and artificial intelligence for the early detection of pancreatic cancer. In 2026, the company was acquired by Liminatus Pharma (Nasdaq: LIMN) in a merger valued at approximately $320 million to bolster Liminatus's oncology pipeline. The company's technology is designed to address critical challenges in cancer treatment, including antigen escape and the immunosuppressive tumor microenvironment.